Online inquiry

IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9706MR)

This product GTTS-WQ9706MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets KLRK1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_007360.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 22914
UniProt ID P26718
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9706MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7381MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ15286MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ8430MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ10047MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ8960MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ8485MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ8079MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ12933MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PankoMab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW